LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
+32.41%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$153M
AUM Growth
+$153M
(+27%)
Cap. Flow
+$11.8M
Cap. Flow
% of AUM
7.71%
Top 10 Holdings %
Top 10 Hldgs %
96.07%
Holding
19
New
6
Increased
4
Reduced
7
Closed
1
Top Buys
| 1 |
TScan Therapeutics
TCRX
|
$13.1M |
| 2 |
GH Research
GHRS
|
$11.5M |
| 3 |
Merus
MRUS
|
$2.23M |
| 4 |
Cullinan Oncology
CGEM
|
$1.24M |
| 5 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
$1.05M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$6.24M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$4.79M |
| 3 |
Cabaletta Bio
CABA
|
$3.53M |
| 4 |
Passage Bio
PASG
|
$2.11M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$1.81M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Merus
MRUS
$4.98B
| $30.3M | 19.88% |
1,152,525
+84,802
| +8% | +$2.23M |
|
|
2
Cabaletta Bio
CABA
$133M
| $28.2M | 18.45% |
2,181,377
-273,250
| -11% | -$3.53M |
|
|
ALPN
3
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $27.5M | 17.99% |
2,670,472
-465,701
| -15% | -$4.79M |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $13.2M | 8.65% |
1,205,050
-164,877
| -12% | -$1.81M |
|
|
5
TScan Therapeutics
TCRX
$102M
| $13.1M | 8.56% |
+5,224,600
| New | +$13.1M |
|
|
6
GH Research
GHRS
$837M
| $11.5M | 7.54% |
+969,374
| New | +$11.5M |
|
|
PRDS
7
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $7.06M | 4.63% |
3,902,434
+578,373
| +17% | +$1.05M |
|
|
THRX
8
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $7.06M | 4.63% |
757,009
-4,249
| -0.6% | -$39.6K |
|
|
KNTE
9
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $6.21M | 4.07% |
2,048,736
-165,514
| -7% | -$502K |
|
10
Neurogene
NGNE
$264M
| $2.57M | 1.68% |
3,094,554
+666,231
| +27% | +$553K |
|
|
PVLA
11
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $1.62M | 1.06% |
9,775,849
+2,708,131
| +38% | +$448K |
|
|
12
Cullinan Oncology
CGEM
$445M
| $1.24M | 0.81% |
+115,063
| New | +$1.24M |
|
|
13
Passage Bio
PASG
$22.7M
| $1.1M | 0.72% |
1,167,343
-2,240,255
| -66% | -$2.11M |
|
14
Structure Therapeutics
GPCR
$1.11B
| $956K | 0.63% |
23,000
| – | – |
|
15
Athira Pharma
ATHA
$15.3M
| $571K | 0.37% |
+193,573
| New | +$571K |
|
16
Pharvaris
PHVS
$1.39B
| $321K | 0.21% |
21,225
-5,000
| -19% | -$75.7K |
|
|
CMPS
17
Compass Pathways
CMPS
$424M
| $167K | 0.11% |
+20,114
| New | +$167K |
|
|
DBVT
18
DBV Technologies
DBVT
$264M
| $34.7K | 0.02% |
+18,265
| New | +$34.7K |
|
|
BLU
19
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-866,646
| Closed | -$6.24M |
|